A2a Receptor Modulation for T Cell Tolerance Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective long-term enhancement of immune responses to specific antigens and fail to reduce the need for chronic immunosuppressive therapies, particularly in treating abnormal cell proliferation and infectious diseases.
Innovation Solution
A2a receptor antagonists are administered to overcome T cell tolerance by increasing IFN-γ release, reducing regulatory T cell production, and enhancing antigen-specific memory T cell production, while A2a receptor agonists induce long-term T cell tolerance to reduce immune responses and minimize immunosuppressive agent use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If T cell tolerance is maintained to prevent autoimmunity, then autoimmune reactions are prevented, but immune responses to antigens and infections are suppressed
Solution Approach 1:
The patent applies local quality by differentiating between self-antigens and foreign antigens in the mechanism of T cell tolerance. A2a receptor agonists selectively enhance tolerance to self-antigens while A2a receptor antagonists selectively enhance responses to foreign antigens, allowing the immune system to have different functional states for different targets simultaneously.
Solution Approach 2:
The patent implements dynamics by using reversible modulation of T cell tolerance through adenosine receptor ligands. The tolerance state is not fixed but can be dynamically adjusted - enhanced by agonists when autoimmunity prevention is needed, and reduced by antagonists when immune response to pathogens or tumors is required.
2Reliability
If chronic immunosuppressive therapy is used to maintain T cell tolerance, then rejection of transplanted organs is prevented, but long term immune responses are suppressed and side effects increase
Solution Approach 1:
The patent applies preliminary action by using A2a receptor agonists during the induction phase of transplantation to establish long-term T cell tolerance to donor antigens. This preliminary tolerance induction allows reduction or discontinuation of chronic immunosuppressive therapy, as the tolerance mechanism is already established and maintained without continuous drug intervention.
Solution Approach 2:
The patent employs short-term administration of A2a receptor agonists as a disposable induction strategy rather than requiring continuous expensive chronic immunosuppression. The initial short-term treatment establishes a self-sustaining tolerance mechanism that persists without ongoing pharmacological intervention.
3Reliability
If A2a receptor agonists are used to enhance T cell tolerance, then immune responses are reduced and immunosuppression is minimized, but long term enhancement of immune responses is lost
Solution Approach 1:
The patent applies inversion by using A2a receptor antagonists instead of agonists to achieve long-term immune response enhancement. Rather than trying to maintain elevated immune responses continuously (which would require chronic stimulation), the invention inverts the approach by blocking tolerance mechanisms with antagonists, allowing the immune system to naturally maintain enhanced responsiveness without continuous intervention.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
A2a receptor antagonists enhance immune responses against antigens and infections, and agonists reduce the need for chronic immunosuppression, improving treatment outcomes for cancer and autoimmune diseases by modulating T cell responses effectively.
Implementation Method 1
A2a receptor antagonists are administered to overcome T cell tolerance by increasing IFN-γ release
Implementation Method 2
A2a receptor agonists induce long-term T cell tolerance to reduce immune responses and minimize immunosuppressive agent use
Data Source
AI summary
Described are uses of A2a adenosine receptor antagonists and agonists to provide long term modulation of immune responses. A2a receptor antagonists in particular are provided to enhance immune responses by reducing T-cell mediated tolerance to antigenic stimuli and agonists are provided to enhance effectiveness of immunosuppressive agents. The application provides methods of treatment and prevention based on the long term effects of the compounds on T cell responses.